A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia-A nationwide study

研究成果: Article

8 引文 斯高帕斯(Scopus)

摘要

Background: Risperidone long-acting injection (RLAI), the first licensed, long-acting second-generation antipsychotic (SGA), has not yet been studied in terms of its effectiveness compared with first-generation antipsychotic (FGA) LAIs. Methods: The differences in the effectiveness of RLAI and two other FGA LAIs, haloperidol and flupentixol, were assessed by conducting a one-year pre-post study based on the Taiwanese National Health Insurance Research Database. Effectiveness was defined as reduced medical care utilization and relapse prevention. Results: A decreased number of relapses were identified in the haloperidol injection group in the post-LAI period than in the pre-LAI period (Wilcoxon signed rank test, p. <. 0.05). The RLAI group had the largest number of acute admissions and relapses, the longest duration of admission (Wilcoxon signed rank test, p. <. 0.005), and the lowest utilization of anticholinergic agents, such as benzodiazepine (BZD) and SGAs (except oral risperidone), among all of the LAI groups in the post-LAI period. Conclusions: According to the results of this observational study, we suggest that the effectiveness of RLAI is not superior to that of FGA (haloperidol or flupentixol) LAIs, but that RLAI might have fewer adverse effects.

原文English
頁(從 - 到)400-405
頁數6
期刊Schizophrenia Research
169
發行號1-3
DOIs
出版狀態Published - 2015 十二月 1

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

指紋 深入研究「A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia-A nationwide study」主題。共同形成了獨特的指紋。

  • 引用此